Quest Diagnostics (DGX) EBT (2009 - 2026)

Quest Diagnostics has reported EBT for 18 years, with the latest figure at $412.0 million in Q2 2026.

• Quarterly EBT rose 7.29% year-over-year to $412.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 11.87% YoY) and the FY2025 annual result came in at $1.3 billion, up 12.17% from the prior year.
• EBT grew to $412.0 million in Q2 2026 per DGX's latest filing, from $334.0 million in the prior quarter.
• Over five years, EBT peaked at $452.0 million in Q1 2022 and troughed at $109.0 million in Q4 2022.
• A 5-year average of $311.3 million and a median of $315.5 million in 2023 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2023: EBT plunged 78.29% in 2022, then surged 117.43% in 2023.
• Over 5 years, EBT stood at $109.0 million in 2022, then soared by 117.43% to $237.0 million in 2023, then increased by 26.16% to $299.0 million in 2024, then grew by 10.37% to $330.0 million in 2025, then gained by 24.85% to $412.0 million in 2026.
• According to Business Quant data, EBT over the past three periods registered $412.0 million, $334.0 million, and $330.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.